Pfizer : PFE

All Pfizer Articles

1515 Articles

Jon C. Ogg | May 27, 2014 at 8:55 AM EDT

The Dangers of Chasing Hopeful Merger and Buyout Stocks

ThinkstockEvery time the economy gets good again, and every time the stock market gets high again, waves of mergers and…

Trey Thoelcke | May 22, 2014 at 8:20 AM EDT

Why You Buy Big Pharma If the Market Crashes

A new report from the global equity strategy team at Credit Suisse maintains that the best defensive sector now is…

Jon C. Ogg | May 21, 2014 at 7:40 AM EDT

Dividend Shock: Over Half of DJIA Blue Chips Outyield 10-Year Treasury

Several things are taking place ahead of the end of May, and the number of pundits getting more worried about…

Paul Ausick | May 19, 2014 at 4:01 PM EDT

The 4 Stocks That Propped Up the Dow

thinkstockMay 19, 2014: Markets opened lower on Monday but look to close the day on the upside, even if just…

Douglas A. McIntyre | May 19, 2014 at 3:11 PM EDT

Pfizer Rises, AT&T Sinks to Lead the Dow’s Action

ThinkstockBig news from two of the market’s biggest names is making waves across Wall Street today as stocks advance through a…

Vince Calio | May 8, 2014 at 10:53 AM EDT

The Best-Selling Products of All Time

ThinkstockCreating the most popular product of the year will make consumers and investors happy. But making an all-time bestseller can…

Paul Ausick | May 6, 2014 at 4:01 PM EDT

The 4 Stocks That Tanked the Market

thinkstockMay 6, 2014: Markets opened lower on Monday and sank slowly and surely for the rest of the day. The…

Paul Ausick | May 6, 2014 at 11:05 AM EDT

Cross-Border Premium Implications in Merck-Bayer Transaction

Merck has had its consumer products business on the market since the beginning of this year, and Tuesday it announced…

Paul Ausick | May 5, 2014 at 4:01 PM EDT

The 4 Stocks That Moved the Markets

thinkstockMay 5, 2014: Markets opened lower on Monday but gamely pushed to the upside in midafternoon. General concern over the…

Paul Ausick | May 5, 2014 at 8:00 AM EDT

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

Drug giant Pfizer reported better-than-expected first-quarter 2014 earnings before markets opened Monday morning, but revenues fell short. Shares traded lower…

Jon C. Ogg | May 4, 2014 at 10:32 AM EDT

The Top Eight Earnings for the Week Ahead

Jon OggEarnings season is far from over, but roughly three quarters of the stocks in the Standard & Poor’s 500 Index…

Paul Ausick | May 2, 2014 at 8:55 AM EDT

AstraZeneca Declares Pfizer Bid ‘Inadequate’

British drug maker AstraZeneca once again rejected a takeover bid from U.S. pharmaceutical giant Pfizer, this one worth $106 billion…

Paul Ausick | Apr 28, 2014 at 4:01 PM EDT

The 4 Stocks That Led Markets Higher

thinkstockApril 28, 2014: Markets opened higher on Monday with little economic data to drive the market either up or down.…

cgblaine22 | Apr 26, 2014 at 8:30 AM EDT

Biotech: The Poster Child for Market Volatility in 2014

The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5.…

Jon C. Ogg | Apr 23, 2014 at 8:50 AM EDT

UBS Top Stocks to Buy Working for Cancer Cures

In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are…

1 … 67 68 69 70 71 … 101

Pfizer : PFE

All Pfizer Articles

The Dangers of Chasing Hopeful Merger and Buyout Stocks

Why You Buy Big Pharma If the Market Crashes

Dividend Shock: Over Half of DJIA Blue Chips Outyield 10-Year Treasury

The 4 Stocks That Propped Up the Dow

Pfizer Rises, AT&T Sinks to Lead the Dow’s Action

The Best-Selling Products of All Time

The 4 Stocks That Tanked the Market

Cross-Border Premium Implications in Merck-Bayer Transaction

The 4 Stocks That Moved the Markets

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

The Top Eight Earnings for the Week Ahead

AstraZeneca Declares Pfizer Bid ‘Inadequate’

The 4 Stocks That Led Markets Higher

Biotech: The Poster Child for Market Volatility in 2014

UBS Top Stocks to Buy Working for Cancer Cures

QQQI Yields You Almost 14%, but Can It Survive a Dot-Com-Style Recession?

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America's Debt Just Crossed a Level It Hasn't Hit Since 1946, and Households Are Next in Line

QQQI Yields You Almost 14%, but Can It Survive a Dot-Com-Style Recession?

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

Pfizer : PFE

All Pfizer Articles

The Dangers of Chasing Hopeful Merger and Buyout Stocks

Why You Buy Big Pharma If the Market Crashes

Dividend Shock: Over Half of DJIA Blue Chips Outyield 10-Year Treasury

The 4 Stocks That Propped Up the Dow

Pfizer Rises, AT&T Sinks to Lead the Dow’s Action

The Best-Selling Products of All Time

The 4 Stocks That Tanked the Market

Cross-Border Premium Implications in Merck-Bayer Transaction

The 4 Stocks That Moved the Markets

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

The Top Eight Earnings for the Week Ahead

AstraZeneca Declares Pfizer Bid ‘Inadequate’

The 4 Stocks That Led Markets Higher

Biotech: The Poster Child for Market Volatility in 2014

UBS Top Stocks to Buy Working for Cancer Cures

QQQI Yields You Almost 14%, but Can It Survive a Dot-Com-Style Recession?

XOP vs. OIH: Do Drillers or Service Providers Best Ride Crude Above $100?

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

Featured Reads

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America's Debt Just Crossed a Level It Hasn't Hit Since 1946, and Households Are Next in Line